New study finds a promising combined therapy for multiple sclerosis

Researchers from Barcelona’s Germans Trias i Pujol Institute and Josep Carreras Leukaemia Research Institute have found a potential new way to improve the treatment of multiple sclerosis (MS) using a

Key pathway leading to neurodegeneration in early stages of ALS identified

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers

Investigational drug for genetic form of ALS improves disease’s molecular signs

An investigational drug developed to treat a rare, inherited form of amyotrophic lateral sclerosis (ALS) reduced molecular signs of the fatal, paralyzing disease and curbed neurodegeneration — but at six